Leucine intake for Healthy Subjects (HS)

Phase-Based Progress Estimates
The Hospital for Sick Children, Toronto, Canada
Healthy Subjects (HS)
Leucine - DietarySupplement
18 - 65
All Sexes
What conditions do you have?

Study Summary

The purpose of the study is to determine the body's nutritional need for the essential amino acid, leucine, in adult men and women 18 to 39 years of age.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Healthy Subjects (HS)

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 4.5 hours during study visits

Hour 5
13C-phenylalanine enrichment
at end of each study visit
Plasma amino acid concentrations

Trial Safety

Safety Progress

1 of 3

Other trials for Healthy Subjects (HS)

Trial Design

1 Treatment Group

Leucine intake
1 of 1
Experimental Treatment

32 Total Participants · 1 Treatment Group

Primary Treatment: Leucine intake · No Placebo Group · N/A

Leucine intake
Experimental Group · 1 Intervention: Leucine · Intervention Types: DietarySupplement
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 4.5 hours during study visits

Trial Background

Glenda Courtney-Martin, Associate Scientist
Principal Investigator
The Hospital for Sick Children
Closest Location: The Hospital for Sick Children · Toronto, Canada
Photo of Toronto  1Photo of Toronto  2Photo of Toronto  3
2014First Recorded Clinical Trial
24 TrialsResearching Healthy Subjects (HS)
398 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are between the ages of 18 and 39 and have regular menstrual cycles within the last 12 months.
You have a BMI between 18.5 and 27 kg/m 2.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.